Dr. Benjamin A. Weinberg, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
3800 Reservoir Rd Nw, Department Of Medicine
Washington, DC 20007
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 145
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
DC license MD040203 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medstar Washington Hospital Center Washington, DC
- Medstar Georgetown University Hospital Washington, DC
- Medstar Montgomery Medical Center Olney, MD
Medical groups
- Medstar Medical Group II LLC (3,767 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 145
- Services billed
- 498
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 169 | 65 |
| Established patient office or other outpatient visit, 40-54 minutes | 137 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 49 | 34 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 25 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Washington, DC | 37 |
| Oxycodone Hcl Other prescribers in Washington, DC | 34 |
| Creon (lipase/protease/amylase) Other prescribers in Washington, DC | 29 |
| Ondansetron Hcl Other prescribers in Washington, DC | 23 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Washington, DC | 22 |
| Pantoprazole Sodium Other prescribers in Washington, DC | 22 |
| Prochlorperazine Maleate Other prescribers in Washington, DC | 22 |
| Prednisone Other prescribers in Washington, DC | 19 |
| Sunitinib Malate | 13 |
| Abiraterone Acetate | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 77 payments worth $66,778 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $38,982 |
|---|---|
| Pfizer Inc. | $11,037 |
| Partner Therapeutics, Inc. | $7,047 |
| Sirtex Medical Inc | $6,491 |
| Array Biopharma Inc | $1,966 |
| Caris Mpi, Inc. | $450 |
| Lilly USA, LLC | $425 |
| Exelixis Inc. | $307 |
| Compensation for services other than consulting (speaking, faculty) | $36,490 |
|---|---|
| Consulting Fee | $21,175 |
| Travel and Lodging | $7,243 |
| Food and Beverage | $1,870 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Sep 5, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $8,850 |
| Jazz Pharmaceuticals Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Partner Therapeutics, Inc. Mar 13, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $5,625 |
| Sirtex Medical Inc Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) SIR-Spheres Microspheres · Interventional Oncology | $5,500 |
| Jazz Pharmaceuticals Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $5,310 |
| Pfizer Inc. Mar 14, 2025 | Consulting Fee XELJANZ · GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | $5,125 |
| Pfizer Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $4,250 |
| Jazz Pharmaceuticals Inc. Apr 30, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind | $852 |
All 47 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Sep 5, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $8,850 |
| Jazz Pharmaceuticals Inc. Jul 23, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Caris Mpi, Inc. Jul 10, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $300 |
| Caris Mpi, Inc. Jun 12, 2025 | Consulting Fee MI CANCER SEEK · ONCOLOGY | $150 |
| Pfizer Inc. May 31, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind | $505 |
| Pfizer Inc. May 29, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind | $213 |
| Pfizer Inc. May 21, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind | $104 |
| Pfizer Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $4,250 |
| Jazz Pharmaceuticals Inc. May 12, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind | $57.86 |
| Jazz Pharmaceuticals Inc. May 7, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Jazz Pharmaceuticals Inc. May 5, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $5,310 |
| Jazz Pharmaceuticals Inc. Apr 30, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind | $852 |
| Jazz Pharmaceuticals Inc. Apr 30, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Baltimore, MD · in-kind | $70.00 |
| Jazz Pharmaceuticals Inc. Apr 30, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Baltimore, MD · in-kind | $16.65 |
| Sirtex Medical Inc Apr 26, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to CLEVELAND, OH | $126 |
| Jazz Pharmaceuticals Inc. Apr 24, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind | $338 |
| Jazz Pharmaceuticals Inc. Apr 16, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind | $138 |
| Jazz Pharmaceuticals Inc. Apr 16, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind | $127 |
| Sirtex Medical Inc Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) SIR-Spheres Microspheres · Interventional Oncology | $5,500 |
| Pfizer Inc. Apr 11, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Saint Louis, MO · in-kind | $649 |
| Sirtex Medical Inc Apr 11, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to DULLES, VA | $74.26 |
| Sirtex Medical Inc Apr 11, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to DULLES, VA | $47.89 |
| Sirtex Medical Inc Apr 11, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to WESTLAKE, OH | $33.91 |
| Sirtex Medical Inc Apr 11, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to WESTLAKE, OH | $31.93 |
| Sirtex Medical Inc Apr 11, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to WESTLAKE, OH | $14.91 |
| Array Biopharma Inc Apr 9, 2025 | Compensation for services other than consulting (speaking, faculty) BRAFTOVI · ONCOLOGY | $190 |
| Sirtex Medical Inc Mar 27, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to CLEVELAND, OH | $484 |
| Sirtex Medical Inc Mar 27, 2025 | Travel and Lodging SIR-Spheres Microspheres · Interventional Oncology · travel to CLEVELAND, OH | $37.50 |
| Jazz Pharmaceuticals Inc. Mar 26, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind | $225 |
| Jazz Pharmaceuticals Inc. Mar 19, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Smithfield, RI · in-kind | $121 |
| Pfizer Inc. Mar 14, 2025 | Consulting Fee XELJANZ · GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | $5,125 |
| Partner Therapeutics, Inc. Mar 13, 2025 | Consulting Fee Bizengri · Hematology/Oncology | $5,625 |
| Partner Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $62.21 |
| Partner Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $52.98 |
| Partner Therapeutics, Inc. Mar 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $45.90 |
| Array Biopharma Inc Mar 2, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Orlando, FL · in-kind | $465 |
| Array Biopharma Inc Mar 2, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Orlando, FL · in-kind | $337 |
| Array Biopharma Inc Mar 2, 2025 | Travel and Lodging BRAFTOVI · ONCOLOGY · travel to Orlando, FL · in-kind | $275 |
| Array Biopharma Inc Feb 28, 2025 | Consulting Fee BRAFTOVI · ONCOLOGY | $700 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA · in-kind | $467 |
| Partner Therapeutics, Inc. Feb 13, 2025 | Travel and Lodging Bizengri · Hematology/Oncology · travel to New Orleans, LA | $454 |
| Jazz Pharmaceuticals Inc. Jan 28, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Paramus, NJ · in-kind | $177 |
| Jazz Pharmaceuticals Inc. Jan 27, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Smithfield, RI · in-kind | $218 |
| Jazz Pharmaceuticals Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $7,080 |
| Lilly USA, LLC Jan 15, 2025 | Consulting Fee CYRAMZA · Oncology | $425 |
| Jazz Pharmaceuticals Inc. Jan 10, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind | $214 |
| Jazz Pharmaceuticals Inc. Jan 10, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Lexington, KY · in-kind | $208 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 9 companies. The companies reported $1,602,389 in research payments for these studies, mostly to the institutions running them.
- NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Ipsen Biopharmaceuticals, Inc · Active, not recruiting · NCT04005339 - STUDY NAME#Phase II Trial of BXCL701 and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma
Merck Sharp & Dohme LLC - Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of XL495 in Solid Tumors
Exelixis Inc. - A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastat…
Janssen Research & Development, LLC - A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
AstraZeneca Pharmaceuticals LP - An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
Pfizer Inc. - A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation - A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC - A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent H…
AstraZeneca UK Limited - A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously…
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.